CD4 and neoplasm: A good prognosis was observed in TNBC in which tumors were highly infiltrated by CD20+ TILs combined with CD4+ and CD8+ TILs; therefore, CD20+ TILs may support CD4+ and CD8+ TILs in altering the anti-tumor response.